CD200 and neoplasm: In both the training dataset and the validation dataset 1, expression of BTLA, CD200, CD28, CD86, HAVCR2, LAIR1, TNFRSF4, and TNFSF4 was upregulated in high risk patients, which indicated the association between the risk score and tumor immunity.